Hematologic Malignancy
Plasma Cell Neoplasm
CI-CAN-00006438Explore in graph →
HematologicNon-malignant831 active trials25 approved drugs26 evidence items
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00006438Explore in graph →
Clinical trials
3,421 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04989140 | Study of Pomalidomide, Oral Dexamethasone and Ixazomib in Patients With Relapsed MM Who Have Received Lenalidomide | unknown | Phase 4 | 60 | Peking Union Medical College HospitalOTHER | 1 | Aug 19, 2021 | clinicaltrials |
| NCT04746092 | The Capability of Haemato-oncology Patients to Generate Antibodies Against COVID-19 | unknown | — | 630 | Tel-Aviv Sourasky Medical CenterOTHER_GOV | 1 | Aug 16, 2021 |
| NCT05006469 | Observation of the Efficacy of BAd Regimen in the Treatment of Relapsed and Refractory Multiple Myeloma | unknown | Phase 3 | 10 | Liao AijunOTHER | 1 | Aug 16, 2021 | clinicaltrials |
| NCT04727294 | MGUS, SMM, and MM Patient Experience With Coronavirus 19 (COVID-19) Survey | unknown | — | 1,500 | HealthTree FoundationOTHER | 1 | Aug 4, 2021 | clinicaltrials |
| NCT04984434 | Phase 1 Study of F182112 in Patients With Relapsed or Refractory Multiple Myeloma | unknown | Phase 1 | 68 | Shandong New Time Pharmaceutical Co., LTDINDUSTRY | 1 | Jul 30, 2021 | clinicaltrials |
| NCT03720041 | Myeloma XIV: Frailty-adjusted Therapy in Transplant Non-Eligible Patients With Newly Diagnosed Multiple Myeloma(FiTNEss) | unknown | Phase 3 | 740 | University of LeedsOTHER | 1 | Jun 15, 2021 | clinicaltrials |
| NCT04236011 | BCMA and CD19 Targeted Fast Dual CAR-T for BCMA+ Refractory/Relapsed Multiple Myeloma | unknown | Early Phase 1 | 15 | Shanghai Changzheng HospitalOTHER | 1 | Jun 15, 2021 | clinicaltrials |
| NCT03670173 | Safety and Efficacy Assessments of Osalmid in Multiple Myeloma | unknown | Phase 1 / Phase 2 | 20 | Shanghai 10th People's HospitalOTHER | 1 | May 19, 2021 | clinicaltrials |
| NCT04891744 | Selinexor in Combination With Thalidomide and Dexamethasone in RRMM | unknown | Phase 1 / Phase 2 | 48 | Li ZhengOTHER | 1 | May 18, 2021 | clinicaltrials |
| NCT03405571 | Validation of the 4TS RAM in the Prevention of Venous Thromboembolism in Patients With Plasma Cell Dyscrasias.(ROADMAP-MM) | unknown | — | 800 | University of AthensOTHER | 1 | Apr 28, 2021 | clinicaltrials |
| NCT03543579 | Cardiovascular Complications of Carfilzomib Treatment | unknown | — | 46 | University of AthensOTHER | 1 | Apr 28, 2021 | clinicaltrials |
| NCT03795597 | Busulfan, Melphalan, Escalating Carfilzomib Conditioning Auto Stem Cell Transplantation for Multiple Myeloma (MM)(BuMelCarAuto) | unknown | Phase 1 / Phase 2 | 36 | Loyola UniversityOTHER | 1 | Apr 26, 2021 | clinicaltrials |
| NCT04659252 | CORONADO (Circulating tumOur pROtein quaNtification cApillary blooD cOvid-19) | unknown | — | 70 | Institute of Cancer Research, United KingdomOTHER | 1 | Mar 11, 2021 | clinicaltrials |
| NCT04003168 | Human BCMA Targeted T Cells Injection Therapy for BCMA-positive Relapsed/Refractory Multiple Myeloma | unknown | Phase 1 | 18 | Hrain Biotechnology Co., Ltd.INDUSTRY | 1 | Mar 1, 2021 | clinicaltrials |
| NCT04762745 | The Efficacy and Safety of Pomalidomide and Bendamustine With Dexamethasone in Relapsed or Refractory Multiple Myeloma | unknown | Phase 1 / Phase 2 | 56 | Sun Yat-sen UniversityOTHER | 1 | Feb 21, 2021 | clinicaltrials |
| NCT04558853 | Clinical Study of Autologous Natural Killer Cells in Multiple Myeloma | unknown | Phase 1 | 12 | Karolinska University HospitalOTHER | 1 | Feb 17, 2021 | clinicaltrials |
| NCT04665076 | Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Plasma Cell Tumors | unknown | N/A | 60 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | Dec 11, 2020 | clinicaltrials |
| NCT04637269 | Anti-BCMA CAR-T Cell Therapy for the R/R Multiple Myeloma | unknown | Early Phase 1 | 16 | Xinqiao Hospital of ChongqingOTHER | 1 | Nov 19, 2020 | clinicaltrials |
| NCT04626752 | CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma | unknown | Early Phase 1 | 50 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | Nov 13, 2020 | clinicaltrials |
| NCT04609150 | Vertebral Fat Quantitative MRI as a Marker of Bone Fragility in Multiple Myeloma (MYELOMEFRAGIQUANTI) | unknown | — | 100 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Nov 6, 2020 | clinicaltrials |
| NCT03380039 | Clinical Study of CAR-BCMA T Cells in Patients With Refractory or Relapsed Multiple Myeloma | unknown | N/A | 6 | Xinhua Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Oct 12, 2020 | clinicaltrials |
| NCT03302403 | Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors | unknown | N/A | 18 | Kang YUOTHER | 1 | Oct 8, 2020 | clinicaltrials |
| NCT03716856 | Clinical Study of CAR-BCMA T in Patients With Refractory or Relapsed Multiple Myeloma | unknown | Phase 1 | 11 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Oct 8, 2020 | clinicaltrials |
| NCT03711864 | Safety and Efficacy of IM21 Car-t Cells in Patients With Recurrent or Refractory BCMA Positive Multiple Myeloma | unknown | Phase 1 | 15 | Peking Union Medical College HospitalOTHER | 1 | Sep 30, 2020 | clinicaltrials |
| NCT04447573 | Immunotherapy With BCMA CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma | unknown | N/A | 20 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | Sep 29, 2020 | clinicaltrials |
| NCT04537442 | Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma | unknown | Phase 1 | 10 | Beijing Immunochina Medical Science & Technology Co., Ltd.INDUSTRY | 1 | Sep 3, 2020 | clinicaltrials |
| NCT04500431 | Clinical Study to Evaluate the Safety and Feasibility of spCART-269 Injection in the Treatment of MM | unknown | Phase 1 | 10 | Shanghai Tongji Hospital, Tongji University School of MedicineOTHER | 1 | Aug 5, 2020 | clinicaltrials |
| NCT04496011 | Effect of the Cycloergometer in Patients Undergoing Hematopoietic Stem Cell Transplantation | unknown | N/A | 30 | Federal University of Health Science of Porto AlegreOTHER | 1 | Aug 3, 2020 | clinicaltrials |
| NCT03669445 | Study Association of Lenalidomide, Ixazomib, Dexamethasone and Daratumumab in Newly Diagnosed Standard Risk Multiple Myeloma(IFM2018-01) | unknown | Phase 2 | 45 | University Hospital, ToulouseOTHER | 1 | Jul 30, 2020 | clinicaltrials |
| NCT03679351 | "FU-IFM2009" Database Post IFM/DFCI 2009 Study(DB-FU-IFM2009) | unknown | — | 675 | University Hospital, ToulouseOTHER | 1 | Jul 30, 2020 | clinicaltrials |
| NCT04275583 | A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3602 Capsule | unknown | Phase 1 | 40 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jun 17, 2020 | clinicaltrials |
| NCT04407858 | Cardiovascular Complications of Carfilzomib(ICARE) | unknown | — | 60 | European Georges Pompidou HospitalOTHER | 1 | Jun 9, 2020 | clinicaltrials |
| NCT04412889 | A Study of BCMA/CD19 Dual-Target CAR-T Cell Immunotherapy for Relapsed or Refractory MM | unknown | Early Phase 1 | 18 | Hebei Yanda Ludaopei HospitalOTHER | 1 | Jun 2, 2020 | clinicaltrials |
| NCT04388735 | Multiple Myeloma (MM) Quality of Life (QOL) Study | unknown | — | 360 | Massachusetts General HospitalOTHER | 1 | May 14, 2020 | clinicaltrials |
| NCT04376957 | Pilot Study of an Oral Chemotherapy Teaching Tool to Improve Adherence in Patients With Multiple Myeloma | unknown | N/A | 60 | Hamilton Health Sciences CorporationOTHER | 0 | May 6, 2020 | clinicaltrials |
| NCT04364724 | CTFEA Myeloma Study | unknown | — | 200 | Tel-Aviv Sourasky Medical CenterOTHER_GOV | 0 | Apr 28, 2020 | clinicaltrials |
| NCT04295018 | A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma | unknown | Phase 1 | 10 | Peking Union Medical College HospitalOTHER | 1 | Mar 4, 2020 | clinicaltrials |
| NCT03385096 | Mel vs BUCY+VP-16 Conditioning Regimen for MM Undergoing Auto-HSCT | unknown | Phase 2 / Phase 3 | 122 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Feb 25, 2020 | clinicaltrials |
| NCT03051841 | CKD-581 + Bortezomib + Dexamethasone in Patients With Previously Treated Multiple Myeloma | unknown | Phase 1 | 18 | Chong Kun Dang PharmaceuticalINDUSTRY | 1 | Feb 24, 2020 | clinicaltrials |
| NCT03150316 | CKD-581 + Lenalidomide + Dexamethasone in Patients With Previously Treated Multiple Myeloma | unknown | Phase 1 | 18 | Chong Kun Dang PharmaceuticalINDUSTRY | 1 | Feb 24, 2020 | clinicaltrials |
| NCT04260490 | Multiple Myeloma and Environmental Exposure to Pesticides in the French West Indies: A Population Based Case-control Study.(MYELODOM) | unknown | — | 600 | Centre Hospitalier Universitaire de la GuadeloupeOTHER | 2 | Feb 7, 2020 | clinicaltrials |
| NCT02577783 | PDD vs PAD to Treat Initially Diagnosed MM | unknown | Phase 4 | 64 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Feb 5, 2020 | clinicaltrials |
| NCT03015922 | Viral Immunotherapy in Relapsed/Refractory Multiple Myeloma(MUKeleven) | unknown | Phase 1 | 4 | University of LeedsOTHER | 1 | Jan 22, 2020 | clinicaltrials |
| NCT03977103 | Irradiation-based Myeloablative Conditioning Followed by Treg/Tcon Immunotherapy in HSCT | unknown | Phase 2 | 80 | University Of PerugiaOTHER | 1 | Jan 13, 2020 | clinicaltrials |
| NCT00505999 | Etiology of Multiple Myeloma: A Case-Control Study | unknown | — | 140 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 2, 2020 | clinicaltrials |
| NCT04212858 | Amplification of Zinc Finger Protein 217 Gene in Multiple Myeloma | unknown | N/A | 100 | Assiut UniversityOTHER | 0 | Dec 30, 2019 | clinicaltrials |
| NCT03436342 | Chemokine Receptor CXCR4-targeting Molecular Imaging for Metabolic Characterization of Multiple Myeloma and Lymphoma | unknown | Early Phase 1 | 100 | Peking Union Medical College HospitalOTHER | 1 | Dec 27, 2019 | clinicaltrials |
| NCT03638206 | Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies | unknown | Phase 1 / Phase 2 | 73 | Shenzhen BinDeBio Ltd.INDUSTRY | 1 | Dec 11, 2019 | clinicaltrials |
| NCT04194931 | Humanized CAR-T Cells of Anti-BCAM and Anti-CD19 Against Relapsed and Refractory Multiple Myeloma | unknown | Phase 1 | 20 | The First Affiliated Hospital of Nanchang UniversityOTHER | 1 | Dec 11, 2019 | clinicaltrials |
| NCT04191941 | Treatment of Hematological Malignancy With Novel CAR-T Cells. | unknown | Early Phase 1 | 9 | Timmune Biotech Inc.INDUSTRY | 1 | Dec 10, 2019 | clinicaltrials |
Data updated 23 days agoSource updated Aug 19, 2021source: clinicaltrials